Princeton, New Jersey, USA and Suzhou, China – May 26, 2026 – Transcenta Holdings Limited (HKEX: 06628), a clinical-stage global biopharmaceutical company with integrated capabilities across biologic drug discovery, development, process development, and manufacturing, announced it has received a RMB 7 million milestone payment from the out-licensing of its HiCB (Highly Integrated Continuous Bioprocessing) platform, alongside significant progress in its CDMO business.
Following the strategic collaboration and non-exclusive technology license agreement signed with EirGenix Inc. (“EirGenix”) (TWSE: 6589) at the end of 2025 and receipt of the associated upfront payment, both companies have now achieved a major technical milestone, triggering the first milestone payment. To date, Transcenta has successfully fulfilled key deliverables under the agreement. The collaboration is progressing steadily, with the goal of implementing HiCB technology for GMP manufacturing at EirGenix’s facilities.
To further advance the commercialization of the HiCB platform, Transcenta recently appointed its former Chief Technology Officer (CTO), Dr. Guangcheng Huang, as Head of Global Partnerships for the HiCB platform. Dr. Huang will lead the global strategy and execution of the platform’s out-licensing initiatives. Under his leadership, Transcenta will continue to expand this non-exclusive licensing model, which allows the company to retain full ownership of the technology while generating revenue through licensing fees, customized CHO media optimization services, and ongoing media supply...

Princeton, New Jersey and Suzhou, China – May 21, 2026 – Transcenta Holding Limited (HKEX: 06628), a clinical-stage global biopharmaceutical company with integrated capabilities in biologic discovery, research and development, process development, and manufacturing, announced that its partner, Inhibrx Biosciences, Inc. (“Inhibrx,” Nasdaq: INBX), recently released positive interim data from a Phase 1/2 clinical study evaluating ozekibart (INBRX-109) in combination with FOLFIRI for the treatment of patients with locally advanced or metastatic, unresectable colorectal cancer (CRC). Inhibrx also announced that it submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) in April 2026 for ozekibart for the treatment of conventional chondrosarcoma.
Under a license agreement executed through its wholly owned subsidiary Hangzhou Y-Antibody BioPharma Co., Ltd. ("HJB"), Transcenta holds exclusive development and commercialization rights to ozekibart (INBRX-109) in mainland China, the Hong Kong Special Administrative Region, the Macau Special Administrative Region, and Taiwan. In light of the positive progress achieved with ozekibart, Transcenta is actively evaluating its development strategy in the Greater China region.
According to Inhib...

Princeton, New Jersey, USA, and Suzhou, China, April 23, 2026 — Transcenta (06628.HK), an international biopharmaceutical company with integrated capabilities in biologic drug discovery, development, process development, and manufacturing, today announced the presentation of preclinical research data for its proprietary LIV1-targeting antibody-drug conjugate (ADC) at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The data show that the drug exhibits significant anti-tumor activity, payload-differentiated efficacy, and favorable tolerability profiles, supporting further development in LIV1-positive solid tumors.
LIV1 is a member of the zinc transporter family, with limited expression in normal tissues but frequently overexpressed in various cancers, including breast cancer (93%), prostate cancer (72%), and lung cancer (10%), making it an attractive cell surface target for ADC drug development.
Transcenta developed 48D6, a novel proprietary humanized anti-LIV1 monoclonal antibody with high affinity, high specificity, and good internalization capability. Evaluated using Retrogenix cell microarray technology, 48D6 was confirmed to have no off-target interactions with other human proteins, validating its high target specificity. Based on 48D6, Transcenta utilized glycosyltransferase-mediated...

Princeton, New Jersey, USA, and Suzhou, China, April 9, 2026 — Transcenta Pharmaceutical (06628.HK), an international biopharmaceutical company in the clinical stage with integrated capabilities in biologic drug discovery, development, process development, and production, announced that its new logo will be officially launched on April 8. The Chinese stock abbreviation will change from 'Transcenta Holding-B' to 'Transcenta Pharmaceutical-B' starting April 13, 2026. The English stock abbreviation, company name, and stock code on the Hong Kong Stock Exchange will remain unchanged.
This change in stock abbreviation aims to more clearly communicate the company's positioning to the market, reinforcing its recognition as a pharmaceutical enterprise focused on the biopharmaceutical field. This will help all stakeholders better understand the company’s business direction and key development areas. The adjustment also aligns with the company's mission to 'develop high-quality innovative biologics using cutting-edge technologies, and provide differentiated and affordable products for patients worldwide.' To maintain consistency in corporate image, the company has simultaneously updated its logo. The new logo will appear on relevant corporate documents, including but not limited to interim and annual reports, announcements, circulars, notices, share certificates, and press releases, and will be displayed on the company’s official website.
This adjustment clearly conveys Transcenta Pharmaceutical's firm commitment to focusing on the biopharmaceutical field and more accurately reflects the company's integrated capabilities based on its three core technology platforms, as well as the core competencies supported by them...

In one refractory pancreatic cancer patient, the target lesion shrank by 86% after six weeks of TST001 treatment and achieved complete remission (CR) after 270 days of treatment.
Princeton, New Jersey, USA, and Suzhou, China, April 8, 2026 — Transcenta Holding (06628.HK), an international biopharmaceutical company with integrated capabilities in biologic drug discovery, development, process development, and manufacturing, will present significant findings at the 2026 AACR Annual Meeting (Abstract No. 2645): its lead asset, osemitamab (TST001), demonstrates clear early activity in pancreatic cancer treatment, with one late-stage patient achieving complete remission (CR), along with antitumor efficacy data from preclinical pancreatic cancer tumor models.
Notably, osemitamab (TST001) has previously received orphan drug designation from the US Food and Drug Administration (FDA) for the treatment of pancreatic cancer patients. At the 2022 International Gastric Cancer Congress (IGCC), related clinical data were disclosed: a pancreatic cancer patient with low Claudin18.2 expression treated with osemitamab (TST001) monotherapy showed sustained partial remission despite disease progression after multiple rounds of chemotherapy. This brings new hope to the treatment of pancreatic cancer, one of the most challenging tumor types, and highlights the breakthrough strength of Chinese innovative drugs on a global scale...

Princeton, New Jersey, USA, and Suzhou, China, March 30, 2026 – Transcenta Holding (06628.HK), an international clinical-stage biopharmaceutical company with fully integrated capabilities in biologic drug discovery, development, process development, and manufacturing, announced today the appointment of Dr. Kuang-Ching Huang as the Global Head of Partnerships for its highly integrated continuous bioprocessing (HiCB) platform. This move aims to advance the global deployment and execution of Transcenta’s technology out-licensing strategy.
Dr. Huang holds a Ph.D. in biochemical engineering from the Massachusetts Institute of Technology and has over 30 years of experience in biopharmaceutical CMC, technology development, and manufacturing. He has participated in seven commercial and six mid-to-late stage projects across recombinant proteins, monoclonal antibodies, and gene therapy, making him an expert in the development of advanced continuous manufacturing technology platforms. Dr. Huang has held senior management positions at Genzyme and Sanofi. After joining Transcenta Group, he served as Chief Technology Officer and Executive Vice President of Process Development, deeply contributing to the creation of the HiCB platform from scratch. In his new role, he will oversee global partnership initiatives, driving the implementation and value creation of the HiCB platform.
Dr. Huang stated, “The HiCB platform offers practical and scalable solutions to the rising costs and increasingly complex challenges in biologics manufacturing. I look forward to collaborating closely with global partners, sharing our expertise, and exploring innovative pathways to enhance global drug production efficiency, product quality, and treatment accessibility.”
...

On March 26-27, the 2026 Future XDC New Drug Conference was held at Chengdu Medical City. In the conference's session on nuclear medicine and RDCs, R&D leaders from nuclear technology organizations, innovative biotech companies, and multinational pharmaceutical firms engaged in in-depth discussions on cutting-edge topics such as trends in international RDC pipelines, dual-targeting technologies, small antibody ligands, AI-based screening, and combination therapies.
Dr. Xue-Ming Qian, Chairman of the Board and CEO of Transcenta Holding, was invited to participate in the conference. He shared with attendees the development logic, key technological breakthroughs, and latest preclinical progress of radiopharmaceutical therapies using antibodies as binding ligands, under the theme 'Exploration of RDC Development Strategies Using Antibodies as Binding Ligands.'
Currently, the integration of radiopharmaceutical diagnostics and therapeutics is rapidly becoming a key direction in precision oncology treatment. The core concept lies in a closed-loop system of 'imaging first, then treatment, with full monitoring throughout.' Traditional radioligand therapy (RLT) predominantly uses small molecules or peptides as carriers, whereas monoclonal antibodies, known for their high specificity, good tumor internalization, and prolonged retention in lesions, are emerging as an important choice for next-generation RLT carriers.
Dr. Xue-Ming Qian first focused on TLX591 (¹⁷⁷Lu-rosopatamab tetraxetan), a benchmark product in antibody-based RLT. TLX591 is used to treat metastatic castration-resistant prostate cancer (mCRPC) and has achieved a median overall survival of 42 months...

Princeton, New Jersey, USA, and Suzhou, China, March 23, 2026 — Transcenta Holding (06628.HK), an international clinical-stage biopharmaceutical company with fully integrated capabilities in biologics discovery, research and development, process development, and manufacturing, today announced that preclinical research findings for two of the company's self-developed pipelines have been successfully selected for poster presentation at the 2026 American Association for Cancer Research (AACR) Annual Meeting. This year’s conference will take place in San Diego, USA, from April 17 to 22, 2026, local time.
The AACR Annual Meeting is a key platform for advancing the field of oncology, where scientists, clinicians, healthcare professionals, cancer survivors, patients, and advocates gather annually to share and discuss the latest breakthroughs in cancer treatment. From population science and prevention to cancer biology, translational medicine, and clinical research, as well as survivorship care and advocacy, the AACR Annual Meeting showcases cutting-edge cancer science and medical advancements across all areas.
The abstract information is disclosed as follows:
Osemitamab (TST001)
Abstract Title:
Characterization of Osemitamab in Pancreatic Cancer Models and Patients
Characterization Study of Osemitamab in Pancreatic Cancer Models and Patients
...

From March 9 to 11, the 5th BioCentury–BayHelix East-West Biopharma Summit was held in Seoul, South Korea. The conference brought together innovative companies, investment firms, and industry leaders from the global biopharmaceutical sector to discuss cross-regional cooperation and development opportunities for biopharmaceutical innovation.
Dr. Xue Ming Qian, Chairman of the Board and CEO of Transcenta Holding, was invited to participate in a panel discussion on March 10, focusing on the theme 'Generating Faster Data via Asia.' He shared insights and practices on how to fully leverage Asian resources to accelerate clinical data generation with industry experts.
Dr. Xue Ming Qian stated that in recent years, China has continuously promoted policy reforms related to clinical trials to enhance the efficiency of innovative drug development. In terms of ethical review, for multi-center clinical trials, the ethical review results from the leading institution can be recognized by other participating institutions, avoiding duplicate reviews. Additionally, ethical assessments for clinical trials can be conducted simultaneously during the application stage without waiting for formal approval, significantly shortening the startup cycle. Regarding genetic resource management, eligible clinical trials can adopt a filing method instead of an approval process, greatly simplifying procedures and providing efficient support for conducting clinical trials of innovative drugs.
Moreover, Transcenta's high-quality CMC capabilities can also accelerate the acquisition of clinical data. The company has previously assisted...